MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4292/wjgpt.v16.i2.105335

Медицинская библиотека · World journal of gastrointestinal pharmacology and therapeutics · 2025

Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel disease: Propensity score-matched cohort study.

Eun Yong, Culpepper-Morgan Joan, Akanmode Abiodun M, Thu Myint B, Sta Lucia Aprilee A, Thearle Marie S, Trousdale Rhonda K

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with inflammatory bowel disease (IBD) are at an increased risk of bacterial pneumonia, contributing to significant morbidity and mortality. While previous studies have identified various risk factors, including medications and comorbidities, the independent contribution of IBD to pneumonia risk remains unclear. We hypothesized that the increased pneumonia risk is primarily driven by factors other than IBD itself.

AIM: To investigate the relative contributions of IBD, comorbidities, and medications to pneumonia risk in patients with IBD.

METHODS

We conducted a retrospective cohort study using the All of Us Research Program database (2010-2022). We matched 2810 participants with IBD 1:1 with controls using four propensity score models: (1) Demographics/Lifestyle only; (2) Plus comorbidities; (3) Plus medications; and (4) All factors combined. Then we used Cox proportional hazards models to assess pneumonia risk and logistic regression to evaluate risk factors.

RESULTS

In the primary analysis of 5620 matched participants, IBD was not independently associated with increased pneumonia risk [hazard ratio (HR) = 1.07, 95%CI: 0.84-1.35] when matched for all factors. However, participants with IBD had significantly higher risk (HR = 2.08, 95%CI: 1.56-2.78) when matched only for demographics and lifestyle factors. Within the IBD cohort, a high comorbidity burden (Charlson Comorbidity Index ≥ 10) [odds ratio (OR) = 12.20, 95%CI: 6.69-23.00] and systemic steroid use (OR = 2.26, 95%CI: 1.21-4.64) were independently associated with increased pneumonia risk.

CONCLUSION

Comorbidities and systemic steroids, rather than IBD itself, drive pneumonia risk. Management should focus on these factors and prioritize vaccination in high-risk patients.

Для цитирования: Eun Yong, Culpepper-Morgan Joan, Akanmode Abiodun M, Thu Myint B, Sta Lucia Aprilee A, Thearle Marie S, Trousdale Rhonda K. Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel disease: Propensity score-matched cohort study.. World journal of gastrointestinal pharmacology and therapeutics. 2025. DOI: 10.4292/wjgpt.v16.i2.105335.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.